Studies a gene variant in people with psoriasis and psoriatic arthritis treated with methotrexate
Studies a gene variant in adults with psoriasis or psoriatic arthritis who take methotrexate.
Plain-language title generated from the registry record
Registry title: Genetic Variation in TRAF3IP2 (rs13190932)
Key facts
- Where
- Qina, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07086924, who can take part
Where in Egypt
- Qena HospitalQina, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- South Valley University
- Trial code
- NCT07086924
- Record updated
- 25 July 2025
- Original description
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.Read full original descriptionShow less
Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.
It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals.
The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.
Inclusion: Patients aged 18 -70years ; the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI > 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist; Willingness to participate: Signed informed consent; Initiating methotrexate (MTX) therapy: For prospective cohort; Availability for follow-up: Patients must be willing and able to attend scheduled visit.
Exclusion: Patients currently undergoing immunosuppressive or systemic therapies; Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932); Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus); Patients with known genetic disorders affect immune system function; Patients with liver or kidney impairment; Patients with allergy or contraindication to methotrexate; Patients with active or uncontrolled infections, including chronic infections like tuberculosis; Pregnancy and lactation.